Richard Parker

Has grant

Country flagUnited Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

North of England Alcohol Team

Open Date: 2023-01-01

Close Date:

Grant: Close

Leeds Hospital Charities Clinical Academic Research Award

Open Date: 2021-03-01

Close Date: 2023-03-01

Grant: Close

Adipose/Liver Inflammatory Crosstalk through Endothelial Chemokine Capture

Open Date: 2015-04-01

Close Date: 2015-10-01

Grant: Close

Travel to industrial collaborators

Open Date: 2014-07-01

Close Date: 2014-09-01

Grant: Close

Role of CXCR6 in Steatohepatitis

Open Date: 2011-12-01

Close Date: 2015-03-01

Articles (9)

Year:

2023

Year:

2023

Summary Background & Aims Patients with liver disease can be stratified for risk of liver‐related ill health by degree of hepatic fibrosis. The Enhanced liver fibrosis (ELF) test was developed to quantify hepatic fibrosis non‐invasively and is widely used. The objective of this review was to identify and synthesise the evidence on the diagnostic accuracy of the ELF test for staging of hepatic fibrosis. Approach & Results Searches of PubMed and EMBASE were conducted between October 2020 and November 2021 to identify studies reporting the diagnostic accuracy of the ELF test compared to histology in liver disease patients. QUADAS‐2 was used to assess risk of bias in each study. Meta‐analysis using the multiple thresholds model described by Steinhauser S, Schumacher M, Rücker G. Modelling multiple thresholds in meta‐analysis of diagnostic test accuracy studies. BMC Med. Res. Methodol. 2016; 16 . 10.1186/s12874‐016‐0196‐1 allowed synthesis of 2 × 2 data at different cut‐offs. Sixty‐three studies were included in this review. These studies included 19,285 patients with or at risk of liver disease from viral hepatitis, Non‐Alcoholic Fatty Liver Disease, Alcohol‐related Liver Disease and other mixed chronic liver diseases. The prevalence of significant fibrosis, advanced fibrosis and cirrhosis was 47.5%, 39.2% and 4.4%, respectively. Cut‐offs with maximal Youden index were generated with AUROC = 0.811 (95% CI: 0.736–0.870), 0.812 (95% CI: 0.758–0.856) and 0.810 (95% CI: 0.694–0.888) to detect significant fibrosis, advanced fibrosis or cirrhosis, respectively. Diagnostic accuracy of the ELF test varied between different liver diseases and cut‐offs to detect each stage with 95% sensitivity or specificity were also generated. Conclusions Meta‐analysis revealed considerable variability in the ability of ELF to stage fibrosis across disease aetiologies. Research has mostly focused on viral hepatitis and NAFLD. There is currently a lack of data on the value of the ELF test in Alcohol‐related liver disease and patients in primary care settings.

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (10)

Tessa Cacciottolo

NIHR Clinical Lecturer in Gastroenterology

University of Cambridge

UNITED KINGDOM
View details

Bin gao

National Institutes of Health

UNITED STATES
View details

Richard Darnton

-

UNITED KINGDOM
View details

Sumita Verma

University Hospitals Sussex NHS Foundation Trust

UNITED KINGDOM
View details

Kushala Abeysekera

University of Bristol

UNITED KINGDOM
View details

Maja Thiele

Odense University Hospital

DENMARK
View details

Keith Bodger

University of Liverpool

UNITED KINGDOM
View details

Steven Masson

Honorary Clinical Senior Lecturer

Newcastle University

UNITED KINGDOM
View details

Kate Glyn-Owen

University of Southampton

UNITED KINGDOM
View details

Ashwin D. Dhanda

-

UNITED KINGDOM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.